Search Results
26 Results Found for “resistant hypertension”
Cardiovascular care continues to evolve in response to increasingly complex clinical realities, where advances in intervention, electrophysiology and population health must be integrated with a more critical appraisal of long-held assumptions. Across disciplines, there is a growing recognition that improving ...
From ACC26, Dr Matt Budoff shared his highlights, including the new cholesterol guidelines and imaging advances position coronary artery calcium scoring at the heart of personalized cardiovascular risk assessment and prevention.
Presented at EHRA 2026 by Dr David Birnie, the OCEAN trial reveals low, brief atrial fibrillation recurrence rates after successful ablation - findings that may support selective anticoagulation discontinuation while reinforcing the need for ongoing follow-up.
At EHRA 2026, new research from Dr Kerollos Abdelsayed highlighted perioperative inflammation as a modifiable driver of conduction disturbances after TAVI, opening the door to novel pharmacologic and device-based solutions.
At EHRA 2026, new research presented by Professor Elaine Chew explores how music-based digital tools can enhance arrhythmia detection and enable personalized, AI-driven approaches to cardiovascular diagnosis and therapy.
At ACC26, Dr Mardi Gomberg-Maitland presented results from the CADENCE trial, showing how sotatercept significantly improves pulmonary hemodynamics in HFpEF-associated pulmonary hypertension, offering hope for the first targeted therapy in this high-risk population.
Hypertension affects over 1.4 billion adults worldwide and remains the leading modifiable risk factor for global cardiovascular (CV) morbidity and mortality. It is responsible for an estimated 10.8 million deaths annually and contributes significantly to the global burden of ischaemic heart disease, ...
Europe loses 1.7 million lives each year to cardiovascular disease, a burden that costs billions and affects millions more. The Safe Hearts Plan sets out an ambitious shift toward prevention, earlier detection and recognition of lifelong genetic risk. As expectations rise, debate is already growing over whether the strategy can translate bold goals into measurable improvements in care and outcomes across the EU.
Hypertension has been associated with increased cardiovascular morbidity and mortality, as well as with overall elevated all-cause mortality.1 Prevalence increases with age, affecting 28.5% of US individuals aged 20–44 years, 58.6% of those aged 45–64 years and 76.5% of those aged 65 years and older.2 In ...
Heart failure (HF) is a global health burden, with a 2019 prevalence of 711.90 per 100,000 population, totalling 56.19 million cases and 5.05 million years lived with disability, despite only modest declines since 1990.1 Recent years have shown an uptick in prevalence, driven by ageing populations ...
Cardiovascular disease (CVD) is one of the major causes of morbidity and mortality throughout the world.1,2 While traditional risk factors are managed intensively, many individuals continue to have considerable residual risk, and emerging factors such as inflammatory mediators are being ...
The 2025 American Heart Association (AHA) Scientific Sessions (7–10 November; New Orleans, LA, USA) offered a comprehensive overview of the evolving landscape of cardiovascular medicine. This year’s research showcased pivotal trials spanning indications, including hypercholesterolemia, hypertrophic cardiomyopathy, amyloidosis, severe hypertriglyceridaemia, hypertension, ...
Coronary artery dissection is a common occurrence during lesion preparation and after drug-coated balloon (DCB) inflation.1 Recent DCB studies focusing on coronary dissections have shown a few key findings: Their angiographic incidence varies between 35 and 60%. Non-flow-limiting dissections left untreated had ...
A phase 3 trial presented at the ESC Congress 2025 reported that the selective aldosterone synthase inhibitor baxdrostat achieved significant reductions in blood pressure in patients with uncontrolled or resistant hypertension.1
The ESC Congress 2025 congress was an important meeting for clinical practice guidance in cardiology, with several major societies releasing long-awaited updates. As always, clinical practice guidelines remain central to cardiology, ensuring that the latest trial data and real-world evidence are rapidly translated into consistent, evidence-based patient care. This year’s congress saw the unveiling of important new documents across prevention, acute care and long-term management, equipping cardiologists with refined decision pathways, updated risk-stratification tools and clearer benchmarks to optimise patient outcomes.
July 2025 marked continued progress in cardiovascular innovation, with notable regulatory decisions and clinical trial milestones. Approvals, designations, and data readouts during the month highlight the field’s ongoing shift toward targeted therapies, gene-based interventions, and outcome-driven evidence. These developments reflect growing momentum in addressing complex and underserved cardiovascular conditions.
Infiltrative cardiomyopathies are a diverse group of cardiac diseases caused by the deposition of abnormal substances within the myocardium and include diseases, such as Fabry disease, sarcoidosis and less common genetic diseases, such as Friedreich’s ataxia and Danon disease.1 ...
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
